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Abstract
Background: Identification of expression alternations between early and late stage cancers is helpful for
understanding cancer development and progression. Much research has been done focusing on stage-dependent
gene expression profiles. In contrast, relatively fewer studies on isoform expression profiles have been performed
due to the difficulty of quantification and noisy splicing. Here we conducted both gene- and isoform-level analysis
on RNA-seq data of 234 stage I and 81 stage IV kidney renal clear cell carcinoma patients, aiming to uncover the
stage-dependent expression signatures and investigate the advantage of isoform expression profiling for
identifying advanced stage cancers and predicting clinical outcome.
Results: Both gene and isoform expression signatures are useful for distinguishing cancer stages. They provide
common and unique information associated with cancer progression and metastasis. Combining gene and isoform
signatures even improves the classification performance and reveals additional important biological processes, such
as angiogenesis and TGF−beta signaling pathway. Moreover, expression abundance of a number of genes and
isoforms is predictive of the risk of cancer death in an independent dataset, such as gene and isoform expression
of ITPKA, the expression of a functional important isoform of UPS19.
Conclusion: Isoform expression profiling provides unique and important information which cannot be detected by
gene expression profiles. Combining gene and isoform expression signatures helps to identify advanced stage
cancers, predict clinical outcome, and present a comprehensive view of cancer development and progression.
Background
Stepwise progression of cancer malignancy has been
clinically well defined [1]. In the early stage, the cancer
cells, confined to a very limited area, are not invasive
and metastatic, whereas in the late stage, the cells,
spreading to distant sites in the body, are highly invasive
and metastatic. Comparative analysis of genetic, epige-
netic, and expression alterations between early and late
stage cancers can help to understand cancer progression
and metastasis mechanisms and predict the clinical
aggressiveness of cancer [1]. Many studies have been
extensively performed on various types of human
cancers [2-22]. For example, molecular mutations were
reported to be accumulated in a fashion that paralleled
the clinical progression of colorectal cancer [5,7,10].
Changes in DNA methylation were also found to be
cumulative with disease progression in ovarian cancer,
gastric cancer and prostate cancer [3,8,11]. Stage-depen-
dent mRNA and microRNA expressions were identified
in neuroblastoma, colon cancer, bladder cancer and gas-
tric cancer [2,4,6,9]. Based on these discovered genetic,
epigenetic, and expression alternations, models of tumor
progression have been constructed, and the process of
tumor progression and metastasis has been studied.
In addition to genetic, epigenetic, and expression
alternations, post-transcriptional deregulation also plays
an important role in cancer progression [17-23]. For
example, alternative splicing of FGFR1 was found to be
associated with tumor stage and grade; isoform switch
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of FGFR1 may result in a proliferative advantage that
plays a key role during bladder tumor progression [18].
Alternative splicing leads to expression changes of speci-
fic isoforms, possibly without overall mRNA expression
alternations. Isoform expression alternations, however,
have not been widely studied partly due to the difficulty
of isoform expression quantification. Recently, RNA-seq
has been increasingly used to discover and profile the
whole transcriptome [24]. The digital nature of RNA-
seq technology coupled with powerful bioinformatics
methods including Alexa-seq [25], IsoEM [26], Multi-
splice [27], MISO [28], Cufflinks [29,30], iReckon [31]
and RSEM [32,33], which aim to quantify isoform
expression accurately, provides the opportunity of sys-
tematically studying expression alternations at isoform
level. However, due to the complexity of transcriptome
and read assignment uncertainty, calculating isoform
abundance from incomplete and noisy RNA-seq data is
still challenging [34]. The advantage of using isoform
expression profiles to identify advanced stage cancers
and predict clinically aggressive cancers remains unclear.
In this study, we performed a comprehensive analysis
on RNA-seq data of 234 stage I and 81 stage IV kidney
renal clear cell carcinoma (KIRC) patients. We identified
stage-dependent gene and isoform expression signatures
and quantitatively compared these two kinds of signa-
tures in terms of cancer stage classification, biological
relevance with cancer progression and metastasis, and
independent clinical outcome prediction. We found that
isoform expression profiling provided unique and
important information that could not be detected at the
gene level. Combining isoform and gene signatures
improved classification performance and presented a
comprehensive view of cancer progression. Further
examination of these signatures discovered well known
and less studied gene and isoform candidates to predict
clinically aggressive cancers.
Methods
RNA-seq data analysis of KIRC
Clinical information and expression quantification
results of RNA-seq data for kidney renal clear cell carci-
noma patients were downloaded from the website of
Broad Institute’s Genome Data Analysis Center (https://
confluence.broadinstitute.org/display/GDAC/Home,
2013_02_03 stddata Run). In total, there are 480 cancer
samples with RNA-seq data, including 234 stage I, 48
stage II, 117 stage III and 81 stage IV patients (Table 1).
RSEM is used to estimate gene and isoform expression
abundance, which is the estimated fraction of transcripts
made up by a given isoform and gene [32,33]. Isoforms
with expression larger than 0.001 TPM (transcript per
million) in at least half of the stage I or stage IV sam-
ples were kept. Limma [35] was applied to identify dif-
ferentially expressed genes and isoforms between 234
stage I and 81 stage IV patients using the criteria: (1)
fold change (FC) ≥ 2 and (2) FDR ≤ 0.001(Benjamini
and Hochberg’s multiple-test adjustment). When signifi-
cant changes were detected at both gene and isoform
levels, only gene signatures were selected for further
analysis.
Classification of cancer stages
Consensus clustering [36] was used to evaluate the
effectiveness of gene and isoform signatures for separat-
ing early and late stage cancers. Consensus clustering is
a resampling-based method to represent the consensus
across multiple runs of a clustering algorithm. Given a
data set of patients with a certain number of signatures,
we resampled the data, partitioned the resampled data
into two clusters, and calculated the classification score
for each resampled dataset based on the agreement of
the clusters with known stages. We defined the classifi-
cation stability score (SS) as a properly normalized sum
of the classification scores of all the resampled datasets
(Eq.1). In the equation, the consensus matrix M(i,j) is
the portion of the resampled dataset {D(h) : h = 1,2,...,H}
in which two patients i and j are clustered together, si
and sj are the known stages of patients i and j, and ES is
the expected stability score of the perfect clustering
where the entry in consensus matrix M equals 1 for
patient pairs with the same stage and the entry equals 0
for patient pairs with different stages. We have 234
stage I and 81 stage IV patients, thus the expected score
of the perfect clustering is 30501. The stability score
estimates how sensitive the clustering results are to
patient variability and indicates the classification perfor-
mance to unknown samples. Here we used Consensu-
sClusterPlus package [37] to subsample signatures and
patients 500 times, whereby a subset of gene/isoform
signatures and patients (80%) was sampled without
replacement from the original dataset. We implemented
Table 1 Characteristics of patients with RNA-seq data for kidney renal clear cell carcinoma
Stage I (n = 234) Stage II (n = 48) Stage III (n = 117) Stage IV (n = 81)
Age, years, mean ± SD 59.9 ± 12.8 58.4 ± 12.0 62.9 ± 12.1 60.8 ± 9.9
Gender, Male, n (%) 145 (62.0%) 36 (75.0%) 76 (65.0%) 56 (69.1%)
Median follow-up, month (minimum - maximum) 37.8 (0.1-112.6) 47.7 (0.1-94.3) 29.5 (0.1-96.0) 18.9 (0.1-87.0)
No. of deaths (%) 38 (16.2%) 8 (16.7%) 45 (38.5%) 64 (79.0%)
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both hierarchical and kmeans clustering algorithms
based on spearman correlation and the stability score of
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Function enrichment
Isoform names were converted into gene symbols by
UCSC Genome Table Browser (http://genome.ucsc.edu/
cgi-bin/hgTables). Functional enrichment analysis on
the list of gene and isoform signatures was implemented
in GO biological process as well as KEGG pathways by
WebGestalt [38] (http://bioinfo.vanderbilt.edu/webges-
talt/). Enrichment p-values were generated by a hyper-
geometric test and adjusted by Benjamini and
Hochberg’s multiple-test. Functional categories with
FDR≤0.05 were selected.
Survival analysis
165 stage II and stage III patients were used as an inde-
pendent dataset to evaluate whether gene and isoform
expression signatures were predictive of increased risk
of cancer death by a Cox proportional hazard (PH)
model. The patients were divided into two groups
according to the median expression value of a given
gene and isoform. Survival analysis was performed
between higher- and lower-than-median groups. Genes
and isoforms with FDR≤0.05 were considered to be sig-
nificantly associated with clinical outcome. A multivari-
ate model adjusting for age and gender of patients was
also performed for selected genes and isoforms.
Results
Isoform profiles provide additional information
We estimated the alternative splicing activity and found
that about 70% of multi-exon genes expressed two or
more isoforms in each sample. This is consistent with the
estimate by Griffith et al.[25], which reported 68% of
multi-exon genes showed evidence for expression of mul-
tiple isoforms. We considered the isoform with the highest
abundance as the “major” isoform and calculated the rela-
tive abundance ratio of the “major” isoform to the corre-
sponding gene. For all genes, about 62% of the major
isoforms had a ratio greater than 0.8 (Additional File 1A,
the mean of ratio was 0.82, Median = 0.93, SD = 0.21).
For genes with multiple isoforms, about 40% of major iso-
forms had a ratio greater than 0.8 (Additional File 1B, the
mean of ratio was 0.71, Median = 0.72; SD = 0.20). These
results indicate that one isoform is more highly expressed
than the others for most genes.
To compare the capacities of gene and isoform
expression profiles to detect alternations, we calculated
the fold change-based correlation between genes and
their major isoforms. The correlation was high for all
genes (Figure 1A, R2 = 0.64, p<2.2e-16) and even higher
if only differentially expressed genes (FC≥2 &
FDR≤0.001) were considered (Figure 1B, R2 = 0.89,
p<2.2e-16), suggesting genes and their major isoforms
are quite consistent in capturing expression changes. In
contrast, the correlation of differentially expressed iso-
forms (FC≥2 & FDR≤0.001) and their corresponding
genes was lower (Figure 1C, R2 = 0.35, p<2.2e-16),
which suggests isoform expression profiling provides
additional information that cannot be detected at the
gene level. This is possibly due to two reasons. One rea-
son may be that isoform switching induces differential
splice variants without gene-level expression changes;
the other reason is that, with only one isoform altered,
the addition of other isoforms to the total gene expres-
sion level simply obscures gene-level expression change.
In total, 567 genes showed significant expression
changes between stage I and stage IV patients (FC≥2 &
FDR≤0.001, Additional File 2). Interestingly, more genes
(1637 vs. 567) were detected significant at the isoform
level than the gene level (Additional File 3, Figure 1D).
Among the 567 gene signatures, 325 genes (57%) had at
least one isoform with significant expression change
(Figure 1D). In contrast, only 20% of genes with signifi-
cantly changed isoforms could be detected at the gene
level. The remaining 80% of the genes with significant
isoforms did not show significant changes at the gene
level, which represents the unique information provided
by isoform expression profiles.
For most genes with significantly changed isoforms,
only one isoform was altered between early and late
stage cancers. Notably, there were only 17 genes with
two or more isoforms showing opposite expression
changes, leading to no expression changes at the gene
level. In these cases, isoform switching mainly contri-
butes to isoform expression alternations. Among the 17
genes, half of them have been reported to be associated
with cell proliferation or cancer progression (Additional
File 4).
Combining gene and isoform signatures improves cancer
stages classification
Having identified stage-dependent gene and isoform
expression signatures, one of the important questions is
to assess the power of these signatures to classify
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unknown samples, which is essential for early cancer
diagnosis. We applied consensus clustering [36], a
resampling-based method to estimate classification sta-
bility and classification accuracy (See Methods for
details). We selected the same number of top-ranked
signatures from genes, isoforms, and combined profiles
(combining gene and isoforms signatures together) to
assess how useful these signatures would be for correctly
separating patients with different stages. We used
agglomerative hierarchical and k-means methods to
implement consensus clustering. The results are similar
(Figure 2). Overall, better performance was achieved
Figure 1 Correlation of gene and isoform profiles in terms of log2 fold changes (FCs). (A) Correlation of genes and major isoforms. (B)
Correlation of differentially expressed genes using the criteria of FC ≥ 2 and FDR ≤ 0.001 and their corresponding major isoforms. Red or green
points depict both significant gene and major isoform up-regulation or down-regulation, respectively. Blue points denote only significant gene
expression changes without major isoform expression changes. (C) Correlation of differentially expressed isoforms using the criteria of FC ≥ 2
and FDR ≤ 0.001 and their corresponding genes. Red or green points depict both significant gene and isoform up-regulation or down-
regulation, respectively. Purple points denote only significant isoform expression changes without gene level changes. (D) Venn diagram
showing the number of genes with significant overall mRNA expression changes and genes with significant isoform expression changes.
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with combined gene and isoform signatures than using
gene and isoform signatures alone. The performance using
isoform signatures deteriorated quickly with the increasing
number of signatures. When the number of signatures
increased from 140 to 220, for example, the classification
stability score dropped from 0.52 to 0.47 and the number
of misclassified patients increased from 57 (accuracy:
81.6%) to 63 (accuracy: 80.0%) using k-means based
consensus clustering (Figure 2A). With hierarchical clus-
tering, the classification stability score dropped from 0.49
to 0.43 and the number of misclassified patients increases
from 54 (accuracy: 82.9%) to 75 (accuracy: 77.1%) (Figure
2B). In contrast, the performance using gene and com-
bined signatures was more robust to the number of signa-
tures used. These results suggest that isoform signatures
are useful for separating cancer stages, but we should be
Figure 2 The performance of gene and isoform signatures in separating cancer stages. (A) The classification stability score obtained by
gene, isoform and combined signatures with k-means clustering algorithms. (B) The classification accuracy obtained by gene, isoform and
combined signatures with k-means clustering algorithms. (C) The classification stability score obtained by gene, isoform and combined
signatures with hierarchical clustering algorithms. (D) The classification accuracy obtained by gene, isoform and combined signatures with
hierarchical clustering algorithms.
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careful about combining isoform information since more
uninformative variables or noise would be introduced at
such a high resolution level.
Combining gene and isoform signatures provides
biological meaningful results
Gene and isoform signatures associated with cancer
stages were interpreted in GO biological process context
as well as in KEGG pathway context (Figure 3, Addi-
tional File 5). A number of pathways involved in tumor
growth, invasion, and metastasis were enriched in both
gene and isoform signatures, which included cytokine-
cytokine receptor interaction, PPAR signaling pathway,
p53 signaling pathway, Calcium signaling pathway, etc.
(Additional File 5). Cytokines and cytokine receptors are
well known to be important contributors to cancer
development and progression [39-42]. PPAR signaling is
responsible for the regulation of cellular events that
range from glucose and lipid homeostasis to cell differ-
entiation and apoptosis, and there is emerging evidence
indicating its anti-proliferative actions or tumor promot-
ing effects [43]. Deregulation of calcium signaling is
regarded as the primary event in the pathogenesis,
growth, invasion, and secondary spread of cancer [44].
As an example, ITPKA was up-regulated in stage IV
patients at both gene (log2FC = 2.14, FDR = 1.8e-10)
and isoform levels (uc001znz.2, log2FC = 1.99, FDR =
1.1e-09). High expression of ITPKA has been reported
to promote migration of tumor cells by two different
mechanisms: ITPKA increases calcium entry that
directly influences cell migration in EGF stimulated
cells. In growth factor poor medium, ITPKA induces the
formation of large cellular protrusions by stabilizing and
bundling actin filaments [45].
In addition, there were important biological pathways
uniquely identified by gene or isoform signatures. Cell
cycle (FDR = 4.0e-04), cell-cell signaling (FDR = 3.0e-
04), regulation of cell proliferation (FDR = 0.005), and T
cell receptor signaling pathways (FDR = 0.05) were only
observed by gene signatures, which are also known to
be associated with tumor progression. For example, the
overall mRNA of FOXA1 was highly expressed in stage
IV patients (log2FC = 3.03, FDR = 2.6e-04). FOXA1 is
involved in cell-cell signaling, and it promotes tumor
progression in prostate cancer [46,47]. Adherens and
tight junctions were only enriched in isoform signatures
(FDR = 2.9e-06, FDR = 6.7e-05). Adherens junction is
involved in establishing and maintaining cell-cell adhe-
sion, and disruption of adherens junctions promotes
tumor cell invasion and metastasis [48-50]. Tight junction
Figure 3 Biological functions and pathways revealed by gene, isoform and combined signatures.
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is critical for maintaining cell to cell integrity and the loss
of cohesion of the structure will lead to invasion and
metastasis of cancer cells[51,52]. Besides, a number of
signaling pathways well known to play a crucial role in
cancer progression were only observed in isoform signa-
tures, including ErbB signaling pathway, MAPK signaling
pathway, Insulin signaling pathway, Wnt signaling path-
way, VEGF signaling pathway, etc. These results suggest
that isoform signatures provide additional insight into the
biological mechanisms related to the tumor progression.
The tight junction gene TJB2, for example, showed differ-
ential expression only at the isoform level (uc011lrs.2,
log2FC=-2.46, FDR = 4.5e-06; uc011lrt.1, log2FC=-2.34,
FDR = 1.8-04). TJP2 is a candidate tumor suppressor
[53] and overexpression of TJP2 will block the cell cycle
and inhibit cell proliferation [54].
Notably, combing gene and isoform signatures not only
uncovered most of the biological processes detected by
gene or isoform profiles but also suggested two additional
critical pathways associated with cancer progression,
angiogenesis (FDR = 2.0e-04) and TGF−beta signaling
pathway(FDR = 0.04). Angiogenesis, the process of form-
ing new blood vessels, allows cancer cells to make their
own blood supply to obtain oxygen and nutrients, which
leads to growth and metastasis [55-57]. The expression of
69 genes involved in angiogenesis was significantly chan-
ged at gene and/or isoform levels. 8 genes involved in the
TGF-beta signaling pathway showed expression alterna-
tions at gene and/or isoform level (Additional File 5).
Gene and isoform signatures predictive with clinical
outcome
We used a Cox proportional hazard (PH) model to eval-
uate whether the detected gene and isoform expression
signatures are predictive of the risk of cancer death. The
165 patients in stage II and stage III of KIRC were
taken as an independent dataset and segregated into
higher- and lower-than-median groups based on the
expression level of the selected gene or isoform. Survival
analysis was performed between these two groups. As a
result, the expression level of 39 genes and 92 isoforms
was found to be significantly associated with survival
time (FDR ≤ 0.05). The 39 genes included ITPKA and
RYR2 (calcium signaling), ITGA8 (regulation of actin
cytoskeleton), FOXA1 and ACTN2 (cell-cell signaling),
NPR3 (cell proliferation), etc. (Additional File 6). The 92
isoforms, corresponding to 86 genes, contained ITPKA
(calcium signaling), ITGA8 (regulation of actin cytoske-
leton), TJP2 (tight junction) and ACVR2A (cytokine-
cytokine receptor interaction), AMOT and BAI1 (angio-
genesis), etc. (Additional File 7). Most of these genes
have been reported to be involved in cancer progress
and metastasis in previous studies.
There were 8 genes whose overall mRNA and isoform
expressions were both associated with clinical outcome,
including ITPKA, ITGA8, OTOF, ZIC2, COL7A1, CILP,
WDR72 and FLRT3. In these cases, the functional iso-
form dominated the gene expression, and thus a similar
signal was obtained at both levels. Consistent with gene-
level expression changes, for example, uc001znz.2, the
major isoform of ITPKA (calcium signaling) was signifi-
cantly up-regulated in the stage IV patients (log2FC =
1.99, FDR = 1.1e-09). In Kaplan-Meier estimates,
patients with higher ITPKA expression in either isoform
or gene level showed lower survival rates (Figures 4A
and 4B). The median survival time was 94.3 months ver-
sus 47.2 months at both gene level and isoform level. In
the univariate Cox PH model, the hazard ratios for
Figure 4 The isoform (uc001znz.2) and gene expression of ITPKA are both predictive of survival in 165 stage II and III patients with
KIRC. Expression value which is lower than median is denoted in green and higher than median is noted in red. Patients with low expression
value show a significantly higher median survival time compared with patients with high expression value (p = 5.0e-05 for the isoform
uc001znz.2 and p = 1.0e-04 for ITPKA).
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ITPKA expression above median were 3.46 (p = 1e-04)
at gene level and 3.67 (p = 5e-05) at isoform level. Mul-
tivariate Cox PH model analysis adjusting for age and
gender was also performed, and ITPKA was also found
to be significantly associated with survival time (p =
0.0005 at gene level and 0.0002 at isoform level). As we
mentioned earlier, ITPKA is a cell motility-promoting
protein that increases the metastatic potential of tumor
cells. The expression of genes and isoforms associated
with cancer stage and clinical outcome make ITPKA the
potential target of advanced stage KIRC therapy.
In some cases, however, background expression of
nonfunctional isoforms added noise to gene abundance
measurements and obscured the gene-level signal.
Therefore, only the signal of functional isoforms could
be observed. As an example, ubiquitin carboxyl-terminal
hydrolase 19 (USP19), a deubiquitinating enzyme that
regulates the degradation of various proteins and plays a
role in cell proliferation and apoptosis, showed no sig-
nificant difference on the overall mRNA expression
between Stage I and Stage IV patients (log2 FC=-0.09,
FDR = 0.12). Simultaneously, the overall mRNA expres-
sion of USP19 was not significantly associated with sur-
vival time (Figure 5D, p = 0.14). In contrast, uc003cvz.3,
the major isoform of USP19 (the relative abundance
ratio = 0.4), was significantly down-regulated in stage IV
patients (log2 FC = -1.24 and FDR= 0.0003), and higher
uc003cvz.3 expression suggested higher survival rates
(Figure 5B). The median survival time for isoform
uc003cvz.3 was 94.3 months versus 49.8 months. In the
univariate Cox PH model, the hazard ratio for uc003cvz.3
expression above the median was 0.37 (p = 0.001). Multi-
variate Cox PH model analysis adjusting for age and gen-
der was also performed and proved that the expression of
isoform uc003cvz.3 was significantly associated with sur-
vival time (p = 0.0005). Besides the isoform uc003cvz.3,
there was another isoform uc003cwa.2 expressed in simi-
lar abundance, which was not significantly changed
between stages and was not associated with survival time
(Figure 5C). Comparing the structure of these two iso-
forms, uc003cvz.3 and uc003cwa.2, we found uc003cvz.3
is longer at N terminal and more functionally important.
Isoform uc003cwa.2 contains only one CS domain, while
uc003cvz.3 has two CS domains (Figure 5A), which play
an important role in the interaction of USP19 with the
cellular inhibitor of apoptosis 2 and influence c-IAP1 and
2-dependent apoptosis [58]. These results suggest that
the expression of the nonfunctional important isoform
uc003cwa.2 obscures the changes of the overall mRNA
expression level of UPS19 and that isoform-level analysis
is sensitive to detect the signal of functional important
isoforms.
Figure 5 Specific isoform expression of USP19 is predictive of survival in 165 stage II and III patients with KIRC. Expression value which
is lower than median is denoted in green and higher than median is noted in red. (A) Transcript structures of two isoforms, uc003cvz.3 and
uc003cwa.2. (B) Patients with high expression value of uc003cvz.3 show a significantly higher median survival time compared with patients with
low expression value (p = 0.001). (C) Patients with high expression value of uc003cwa.2 does not show a significantly higher median survival
time compared with patients with low expression value (p = 0.433). (D) Patients with high expression value of the overall mRNA USP19 do not
show a significantly higher median survival time compared with patients with low expression value (p = 0.138).
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Discussion
Comparative analysis of expression alternations between
early and late stage cancers improves our understanding
of cancer growth and metastasis. Previous studies on
gene expression profiles have identified overall mRNA
expression changes in various kinds of cancers. These
overall mRNA transcript level analyses, however, cannot
uncover post-transcriptional deregulation and may
underestimate the complexity of cancer progression.
Recently, post-transcriptional deregulation such as spli-
cing alternations, a key regulatory process by which
functionally diverse isoforms can be expressed, has been
reported to play an important role in cancer progres-
sion. The abundance of each individual isoform, which
couples both transcriptional and post-transcriptional
regulation, may serve as a valuable source to study the
complexity of cancer progression.
RNA-seq technology, enabling a large dynamic range,
high resolution, and low technical variance in measuring
expression abundance, provides the opportunity of sys-
tematically comparing isoform expression profiles
between early and late stage cancers. In this study, we
not only identified stage-dependent gene and isoform
expression signatures, but also compared the usefulness
of these two kinds of signatures in terms of separating
cancer stages, biological relevance, and prediction of
clinical outcome. Remarkably, about 80% of genes with
significant isoform expression changes do not exhibit
alternations at the overall mRNA level. These isoforms
are useful for separating cancer stages and are enriched
in a number of critical biological function and pathways
associated with cancer progression and metastasis, such
as adherens and tight junctions, ErbB signaling, MAPK
signaling, VEGF signaling pathways, etc. Furthermore,
the expression abundance of a number of isoforms is
significantly associated with the increased risk of death
in an independent dataset. These results demonstrate
that isoform expression profiling provides unique and
important information that cannot be detected by the
gene-level. Isoform-level analysis complements the gene-
level analysis, and combining gene and isoform signa-
tures improves the classification performance and pre-
sents a comprehensive view on the potential biological
mechanisms involved in cancer progression.
Moreover, differential expression observed at the iso-
form level but not at the gene level provides an oppor-
tunity for exploring potential post-transcriptional
regulatory mechanisms to gain insights into isoform
specific regulation. Among 1637 genes with isoform
expression changes, only 17 genes contain two or more
isoforms showing opposite expression changes, which
suggests that isoform switching is not likely to be a
major contributor to splicing pattern changes in cancer
progression. To find RNA binding proteins responsible
for modulating splicing during cancer progression, we
can identify stage-dependent splicing pattern changes
based on the ratio of alternative spliced isoforms and
search for overrepresented nucleotide sequences near
stage-associated splicing events. Additionally, analyzing
the 3’ UTR of genes with differentially expressed iso-
forms is one way to find the miRNA involved in cancer
progression.
Although profiling of individual isoforms provides use-
ful information, we should be careful when we interpret
the results from such a high resolution level. Read
assignment uncertainty inherent in the RNA-seq data
analysis may introduce noise and false positives. Some
reads cannot be assigned unequivocally to an isoform
since many isoforms share exons. This read assignment
uncertainty will affect the accuracy of isoform expres-
sion quantification and introduce noise, especially for
low abundance genes with multiple isoforms. This is
possibly the reason why classification performance drops
quickly with the increasing number of isoform expres-
sion signatures. On the other hand, many isoforms
could be non-functional noise. As a result, the isoforms
detected may simply reflect noisy splicing and are not
likely to be translated into functional proteins [59,60].
For example, one isoform of MLH3 (uc010tuy.1), a
DNA mismatch repair gene without significant changes
at the overall mRNA level (log2FC=-0.04, FDR = 0.6),
was significantly downregulated in the late stage of can-
cer (log2FC=-1.71, FDR = 0.006). However, this isoform
is vulnerable to nonsense-mediated decay and cannot be
translated into protein. As another example, one isoform
of MGRN1 (uc010uxq.1) with significant expression
changes (log2FC = 2.53, FDR = 0.001) was also a non-
coding transcript. Consistently, a previous study has
reported increased levels of noisy splicing in cancers,
leading to marked changes in premature stop-codon fre-
quency for tumor suppressor and oncogenes[60]. Thus
it is important to consider splicing noise when identify-
ing stage-dependent isoform expression signatures. To
reduce the effect of noisy splicing and read assignment
uncertainty, summarizing the reads into more functional
important units, e.g., including only reads that map to
the coding sequences may be more suited for finding
biologically meaningful results.
Conclusion
Isoform expression profiling extends our knowledge
about cancer progression and serves as a useful comple-
ment to gene level analysis. Combining gene and isoform
expression signatures helps to identify advanced stage
cancers and present a comprehensive view on biological
mechanisms in cancer development and progression.
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